pirenzepine has been researched along with Dyspepsia in 10 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Dyspepsia: Impaired digestion, especially after eating.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a double-blind multicentre trial to study the effect of pirenzepine in the treatment of non-ulcer dyspepsia, 104 of 128 patients, 52 in each of the study and control groups, completed the 4 weeks of the investigation." | 9.06 | Campylobacter pylori and non-ulcer dyspepsia. 1. The final results of a double-blind multicentre trial for treatment with pirenzepine in Italy. ( Dobrilla, G; Gad, A, 1989) |
| "Fifty patients (with non-ulcer dyspepsia) were admitted to a double-blind, placebo-controlled trial to study the effects of pirenzepine (100 mg/daily) on non-ulcer dyspepsia." | 9.05 | Pirenzepine in non-ulcer dyspepsia. A double-blind, placebo controlled trial. ( Accardo, P; D'Imperio, N; Dal Monte, PR; Daniotti, S, 1982) |
| "The effectiveness of pirenzepine at 50 mg daily in the treatment of non-ulcer dyspepsia was assessed in a double-blind 4-weeks clinical trial against placebo." | 9.05 | Effect of pirenzepine in the treatment of non-ulcer dyspepsia. A double-blind study. ( Hradsky, M; Wikander, M, 1982) |
| "Pirenzepine was not superior to placebo in decreasing symptoms." | 6.66 | Randomized, double-blind, placebo-controlled crossover trial of cimetidine and pirenzepine in nonulcer dyspepsia. ( Hayden, A; McNeil, D; Piper, DW; Talley, NJ, 1986) |
| "Pirenzepine is a 'selective' antimuscarinic agent which, unlike classic anticholinergic agents, inhibits gastric acid secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular and urinary functions." | 6.37 | Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. ( Brogden, RN; Carmine, AA, 1985) |
| "In a double-blind multicentre trial to study the effect of pirenzepine in the treatment of non-ulcer dyspepsia, 104 of 128 patients, 52 in each of the study and control groups, completed the 4 weeks of the investigation." | 5.06 | Campylobacter pylori and non-ulcer dyspepsia. 1. The final results of a double-blind multicentre trial for treatment with pirenzepine in Italy. ( Dobrilla, G; Gad, A, 1989) |
| "Antral biopsy specimens from 89 consecutive patients with nonulcer dyspepsia and erosive prepyloric changes included in a prospective, randomized, double-blind 4-wk study of the effect of an aluminum-magnesium antacid (120 mmol/day) or pirenzepine (50 mg b." | 5.06 | Antacids reduce Campylobacter pylori colonization without healing the gastritis in patients with nonulcer dyspepsia and erosive prepyloric changes. ( Alexander, B; Berstad, A; Hirschowitz, BI; Holland, S; Serck-Hanssen, A; Weberg, R, 1988) |
| "Fifty patients (with non-ulcer dyspepsia) were admitted to a double-blind, placebo-controlled trial to study the effects of pirenzepine (100 mg/daily) on non-ulcer dyspepsia." | 5.05 | Pirenzepine in non-ulcer dyspepsia. A double-blind, placebo controlled trial. ( Accardo, P; D'Imperio, N; Dal Monte, PR; Daniotti, S, 1982) |
| "The effectiveness of pirenzepine at 50 mg daily in the treatment of non-ulcer dyspepsia was assessed in a double-blind 4-weeks clinical trial against placebo." | 5.05 | Effect of pirenzepine in the treatment of non-ulcer dyspepsia. A double-blind study. ( Hradsky, M; Wikander, M, 1982) |
| "The results of placebo-controlled clinical trials of the treatment of non-ulcer dyspepsia with antacids, H2-receptor blockers, pirenzepine, sucralfate and colloidal bismuth subcitrate are reviewed." | 4.78 | [Drug therapy of non-ulcer dyspepsia]. ( Bytzer, P, 1991) |
| "Pirenzepine was not superior to placebo in decreasing symptoms." | 2.66 | Randomized, double-blind, placebo-controlled crossover trial of cimetidine and pirenzepine in nonulcer dyspepsia. ( Hayden, A; McNeil, D; Piper, DW; Talley, NJ, 1986) |
| "Pirenzepine is a 'selective' antimuscarinic agent which, unlike classic anticholinergic agents, inhibits gastric acid secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular and urinary functions." | 2.37 | Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. ( Brogden, RN; Carmine, AA, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (90.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lagarde, SP | 1 |
| Spiro, HM | 1 |
| Dal Monte, PR | 1 |
| D'Imperio, N | 1 |
| Accardo, P | 1 |
| Daniotti, S | 1 |
| Hradsky, M | 1 |
| Wikander, M | 1 |
| Bytzer, P | 1 |
| Dobrilla, G | 2 |
| Comberlato, M | 1 |
| Steele, A | 1 |
| Vallaperta, P | 1 |
| Gad, A | 1 |
| Weberg, R | 2 |
| Berstad, A | 2 |
| Alexander, B | 1 |
| Serck-Hanssen, A | 1 |
| Holland, S | 1 |
| Hirschowitz, BI | 1 |
| Talley, NJ | 1 |
| McNeil, D | 1 |
| Hayden, A | 1 |
| Piper, DW | 1 |
| Carmine, AA | 1 |
| Brogden, RN | 1 |
3 reviews available for pirenzepine and Dyspepsia
| Article | Year |
|---|---|
Non-ulcer dyspepsia.
Topics: Antacids; Benzodiazepinones; Diet; Duodenitis; Dyspepsia; Gastric Acid; Gastritis; Gastrointestinal | 1984 |
[Drug therapy of non-ulcer dyspepsia].
Topics: Antacids; Bismuth; Dyspepsia; Histamine H2 Antagonists; Humans; Omeprazole; Pirenzepine; Sucralfate | 1991 |
Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases.
Topics: Benzodiazepinones; Dialysis; Dyspepsia; Gastric Acid; Gastrins; Gastrointestinal Hormones; Humans; I | 1985 |
7 trials available for pirenzepine and Dyspepsia
| Article | Year |
|---|---|
Pirenzepine in non-ulcer dyspepsia. A double-blind, placebo controlled trial.
Topics: Adult; Benzodiazepinones; Clinical Trials as Topic; Double-Blind Method; Dyspepsia; Endoscopy; Femal | 1982 |
Effect of pirenzepine in the treatment of non-ulcer dyspepsia. A double-blind study.
Topics: Adult; Benzodiazepinones; Clinical Trials as Topic; Double-Blind Method; Dyspepsia; Female; Humans; | 1982 |
Drug treatment of functional dyspepsia. A meta-analysis of randomized controlled clinical trials.
Topics: Clinical Trials as Topic; Dyspepsia; Gastrointestinal Motility; Histamine H2 Antagonists; Humans; Me | 1989 |
Campylobacter pylori and non-ulcer dyspepsia. 1. The final results of a double-blind multicentre trial for treatment with pirenzepine in Italy.
Topics: Adult; Campylobacter; Campylobacter Infections; Double-Blind Method; Dyspepsia; Female; Humans; Ital | 1989 |
Low-dose antacids and pirenzepine in the treatment of patients with non-ulcer dyspepsia and erosive prepyloric changes. A randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antacids; Clinical Trials as Topic; Double-Blind Method; Dyspepsia; Female; Gastric Mucosa; G | 1988 |
Antacids reduce Campylobacter pylori colonization without healing the gastritis in patients with nonulcer dyspepsia and erosive prepyloric changes.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Campylobacter; Clinical Trials as Topic; Double-Blind Meth | 1988 |
Randomized, double-blind, placebo-controlled crossover trial of cimetidine and pirenzepine in nonulcer dyspepsia.
Topics: Adult; Aged; Benzodiazepinones; Cimetidine; Clinical Trials as Topic; Dyspepsia; Female; Humans; Mal | 1986 |